orforglipron vs Pegloxenatide (Fulaimei)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: May 2027 · NCT07613307 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Pegloxenatide (Fulaimei)
Marketed by Hansoh Pharmaceutical Group and partners
NCT02477969 · Phase 3 · status unknown
This was a randomized, triple-blind, placebo-controlled trial with 587 participants, testing PEX168 against placebo, both added to metformin, using change in HbA1c as the primary measure. A published report of the trial's results describes the primary endpoint as met, with substantially more PEX168 patients than placebo patients reaching HbA1c targets at 24 weeks.
Reported efficacy
HbA1c (Baseline to Week24): Phase 3b add-on-to-metformin trial: proportion achieving HbA1c <7.0% at week 24 was 37.4% (100μg) and 40.6% (200μg) vs 16.8% (placebo). (met)
Result source: NCT02477969
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | orforglipron | Pegloxenatide (Fulaimei) |
|---|---|---|
| HbA1c, change | -1.4% vs -0.1%−1.3 vs placeboNCT0597194014 other results
| —Not reported |
| Body weight, change (kg) | -7.3 vs -1.3−6 vs placeboNCT059719407 other results
| —Not reported |
| HbA1c below 7% | 79.0% vs 37.1%+41.9 vs placeboNCT059719407 other results
| —Not reported |
| Fasting plasma glucose, change | -2.0 vs -1.1−0.9 vs placeboNCT044264744 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT05803421 | —Not reported |
HbA1c, change
- orforglipron
- -1.4% vs -0.1%−1.3 vs placeboNCT05971940
14 other results
- -1.6% vs -0.1% NCT05971940
- -1.3% vs -0.1% NCT05971940
- -2.0% vs -0.4% NCT05048719
- -1.9% vs -0.4% NCT05048719
- -1.2% vs -0.4% NCT05048719
- -2.1% vs -0.4% NCT05048719
- -1.8% vs -0.4% NCT05048719
- -2.0% vs -1.1% NCT05048719
- -1.9% vs -1.1% NCT05048719
- -1.2% vs -1.1% NCT05048719
- -2.1% vs -1.1% NCT05048719
- -1.8% vs -1.1% NCT05048719
- -1.7% vs -0.5% NCT05872620
- 1.7% vs 0.8% NCT06192108
- Pegloxenatide (Fulaimei)
- —Not reported
Body weight, change (kg)
- orforglipron
- -7.3 vs -1.3−6 vs placeboNCT05971940
7 other results
- -5.5 vs -1.3 NCT05971940
- -4.4 vs -1.3 NCT05971940
- -9.5 vs -2.2 NCT05048719
- -6.5 vs -2.2 NCT05048719
- -3.7 vs -2.2 NCT05048719
- -10.1 vs -2.2 NCT05048719
- -9.7 vs -2.2 NCT05048719
- Pegloxenatide (Fulaimei)
- —Not reported
HbA1c below 7%
- orforglipron
- 79.0% vs 37.1%+41.9 vs placeboNCT05971940
7 other results
- 81.3% vs 37.1% NCT05971940
- 78.2% vs 37.1% NCT05971940
- 92.8% vs 24.3% NCT05048719
- 78.9% vs 24.3% NCT05048719
- 65.2% vs 24.3% NCT05048719
- 95.8% vs 24.3% NCT05048719
- 91.2% vs 24.3% NCT05048719
- Pegloxenatide (Fulaimei)
- —Not reported
Fasting plasma glucose, change
- orforglipron
- -2.0 vs -1.1−0.9 vs placeboNCT04426474
4 other results
- -3 vs -1.1 NCT04426474
- -2.9 vs -1.1 NCT04426474
- -2.4 vs -1.1 NCT04426474
- -2.3 vs -1.1 NCT04426474
- Pegloxenatide (Fulaimei)
- —Not reported
3-point MACE (% with event)
- orforglipron
- —Not posted · NCT05803421
- Pegloxenatide (Fulaimei)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. orforglipron: 4 of 4 rows · Pegloxenatide (Fulaimei): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | orforglipron |
|---|---|
| Dropout rate | 6.7%36 mga NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results5.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 5.3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3.5%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 8.8%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 6.3%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 7.4%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 11.8%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.7%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 7.8%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 9.4%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 57.1%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 2.2%36 mga NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results4.4%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.5%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.4%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0.7%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.6%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 35.7%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4.5%36 mga NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results2.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 2.8%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.1%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.6%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2.9%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 1.8%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 5.9%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.1%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%3 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 36 mga constipation 29.1% nausea 27.6% nasopharyngitis 16.4% NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results12 mg constipation 30.4% nasopharyngitis 22.2% nausea 19.3% NCT06010004 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 17.4% constipation 16.7% nausea 12.9% NCT06010004 · Phase 3 · registry result, not featured evidence 36 mg diarrhoea 25.5% (placebo 9.4%) diabetic retinopathy 17% (placebo 15.2%) nausea 17% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 12 mg diarrhoea 21.2% (placebo 9.4%) dyspepsia 21.2% (placebo 7.2%) nausea 19% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 3 mg diarrhoea 18.9% (placebo 9.4%) diabetic retinopathy 14.7% (placebo 15.2%) nausea 12.6% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 36 mg nausea 37% (placebo 5.5%) vomiting 33.3% (placebo 1.8%) diarrhoea 25.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 36 mg nausea 26.5% (placebo 5.5%) vomiting 20.6% (placebo 1.8%) eructation 8.8% (placebo 0%) NCT05048719 · Phase 2 · registry result, not featured evidence 12 mg nausea 37.5% (placebo 5.5%) vomiting 21.4% (placebo 1.8%) diarrhoea 16.1% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 23.5% (placebo 5.5%) diarrhoea 21.6% (placebo 7.3%) constipation 13.7% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg vomiting 35.5% (placebo 1.8%) diarrhoea 29% (placebo 7.3%) nausea 29% (placebo 5.5%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg diarrhoea 28.1% (placebo 7.3%) nausea 25% (placebo 5.5%) vomiting 21.9% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 24 mg nausea 34% (placebo 5.5%) vomiting 27.7% (placebo 1.8%) diarrhoea 14.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 55.6% (placebo 25%) constipation 33.3% (placebo 0%) vomiting 22.2% (placebo 25%) NCT05086445 · Phase 1 · registry result, not featured evidence 2 mg vomiting 40% (placebo 25%) nausea 30% (placebo 25%) abdominal distension 20% (placebo 0%) NCT05086445 · Phase 1 · registry result, not featured evidence 3/6/12/15 mg QD nausea 50% (placebo 5.9%) vomiting 50% (placebo 0%) decreased appetite 40% (placebo 11.8%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21 mg QD nausea 42.9% (placebo 5.9%) decreased appetite 28.6% (placebo 11.8%) covid-19 21.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21/27 mg QD decreased appetite 55.6% (placebo 11.8%) vomiting 55.6% (placebo 0%) nausea 33.3% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9 mg QD vomiting 55.6% (placebo 0%) decreased appetite 44.4% (placebo 11.8%) nausea 44.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9/21/36/45 mg QD nausea 77.8% (placebo 5.9%) decreased appetite 66.7% (placebo 11.8%) vomiting 55.6% (placebo 0%) NCT04426474 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
orforglipron
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Pegloxenatide (Fulaimei)'s landscape